Life Science Investing Incyte Announces Phase 1 Results for its TGF?R2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma 15h
Life Science Investing Data from Incyte's TGF?R2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology Congress 2025 12 October
